Quick answer: Yes — with clear qualifications. Clinical studies show that fractional 1927 nm thulium laser treatment can significantly improve melasma, but it improves pigment rather than curing it, results depend heavily on patient selection and post-treatment care, and recurrence is common. For clinics, the 1927 nm wavelength is valued because its high water absorption keeps the treatment effect shallow, which means less risk of post-inflammatory hyperpigmentation (PIH) than many alternatives. This article gives the honest version of all three: what results the studies actually report, how many sessions protocols typically involve, and what recurrence really looks like.
Key takeaways
- Fractional 1927 nm thulium laser is one of the better-studied laser options for melasma, with documented MASI score reductions in published patient cohorts.
- The wavelength works because it is absorbed strongly by water (not melanin), confining the effect to roughly the upper 200 μm of skin.
- Laser is not where melasma treatment starts. Consensus positioning is photoprotection and topicals first, energy-based devices for refractory cases — the clinics that respect this ladder get the best reviews.
- Realistic framing matters: studies report improvement and visible lightening, not permanent removal.
- Downtime is typically around one week, which affects how clinics should schedule and counsel patients.
- Combination with topicals such as tranexamic acid or hydroquinone is standard maintenance practice — but note that the strongest randomized trial found laser-assisted TXA delivery added no measurable benefit over the laser alone.
- Patient selection — Fitzpatrick skin type, PIH history, epidermal vs. dermal pigment — is the biggest predictor of outcomes.
What Is Melasma and Why Is It Hard to Treat?
Melasma is a chronic pigmentary disorder that presents as symmetric brown or gray-brown patches, most often on the face. It is driven by a combination of ultraviolet exposure, hormonal influences (including pregnancy and oral contraceptives), heat, and a genetically influenced tendency of melanocytes to overproduce melanin. Its chronic, relapsing nature is the core reason it frustrates both patients and providers: pigment can be lightened, but the underlying tendency to re-darken remains.
This reality shapes everything about how a clinic should approach laser treatment — including where laser sits in the treatment ladder. Current clinical consensus structures melasma care in tiers: first-line is rigorous photoprotection plus topical therapy (hydroquinone, triple-combination cream, tranexamic acid); second-line adds chemical peels and, where appropriate, oral tranexamic acid under medical supervision; energy-based devices are third-line, reserved for cases that respond inadequately to topicals or relapse despite them. This is not a reason to avoid offering laser treatment — it is the frame that makes laser treatment succeed. A clinic that sells laser as a first contact for every melasma walk-in will inherit every rebound; a clinic that positions it as the escalation step for managed, sun-disciplined patients gets the outcomes the studies describe.
For clinics, melasma also represents steady, recurring service demand: patients who see genuine improvement typically return for maintenance, making it one of the more sustainable indications to build a practice around. A device that produces excellent short-term lightening can still lead to disappointed patients if the consultation did not set correct expectations about maintenance and recurrence. That is why reputable clinics treat melasma as a long-term management condition rather than a one-time fix, and why any treatment plan should be paired with strict photoprotection and, where appropriate, topical maintenance therapy.
Why the 1927 nm Wavelength?
The platform behind this indication — a 1927 nm thulium laser — emits at a wavelength with a very high absorption coefficient in water. Because water is abundant throughout the epidermis, the laser’s energy is absorbed within a shallow, well-controlled depth — roughly the upper 200 micrometers — which is precisely where most melasma pigment sits. This shallow confinement is the key engineering advantage: deeper structures, including the melanocytes most prone to reactive hyperpigmentation, receive far less energy.
Equally important is what the 1927 nm wavelength does not do. Unlike shorter visible-light wavelengths such as 532 nm, it is not selectively absorbed by melanin, so the risk of heating pigment cells themselves — and triggering PIH, the most feared complication in melasma — is reduced. Modern 1927 nm systems deliver energy in a fractional pattern — thousands of microscopic treatment columns separated by intact skin — which speeds healing and lowers complication rates compared with fully ablative approaches.
The cautionary contrast comes from the older non-ablative fractional workhorse: in a randomized split-face trial of 29 melasma patients, 1,550 nm fractional treatment at 15 mJ/microbeam worsened hyperpigmentation on the laser side versus triple topical therapy, and 31% of patients developed PIH — leading the authors to conclude it was not recommendable for melasma [4]; a companion pilot study found it at best comparable to topicals, with recurrence in both arms [5]. The 1927 nm thulium fiber laser was developed to deliver effective superficial resurfacing with a more forgiving safety profile — which is why it, rather than its 1,550 nm predecessor, became the fractional platform in the melasma conversation. (For background on the platform family, see what is a thulium laser.)
What Does the Clinical Evidence Show?
The published literature is genuinely encouraging — as long as it is read carefully. An early pilot study treated 14 melasma patients with 3–4 sessions of fractional 1927 nm thulium laser (10–20 mJ, 4-week intervals) and reported a statistically significant 51% improvement with no PIH observed [6]. In a larger retrospective review of 100 melasma patients, the mean MASI (Melasma Area and Severity Index) score fell from 11.8 at baseline to 6.7 after the first session and to 3.4 after the second session [1]. A separate split-face study in Asian skin reported significant improvement across both photoaging and melasma parameters after a 4-session thulium course [2].
On combination therapy, a split-face, double-blind randomized trial of 46 patients is worth quoting precisely: four weekly sessions of 1927 nm fractional treatment produced significant mMASI improvement sustained at six months — in both the laser-assisted tranexamic acid group and the laser-only control, with no statistically significant difference between sides [3]. Mild transient hyperpigmentation occurred in a small minority of patients (8.6% TXA side, 6.5% control). In other words, the strongest randomized evidence to date supports the laser itself, while the added value of laser-assisted TXA delivery remains unproven in that trial.
| Study (pop.) | Protokół | Reported result | Caveat |
|---|---|---|---|
| Pilot study, 14 patients [6] | 3–4 sessions, 10–20 mJ, 4-week intervals | 51% improvement, no PIH | Small, uncontrolled pilot |
| Retrospective review, 100 patients [1] | Fractional 1927 nm, 2 sessions, 1-month interval | MASI 11.8 → 6.7 → 3.4 | Retrospective; no long-term recurrence data shown |
| Split-face study, Asian skin [2] | 4-session thulium course | Significant photoaging + melasma improvement | Split-face design; adjunct topicals in protocol |
| Split-face RCT, 46 patients [3] | 4 weekly sessions; laser + TXA vs. laser + saline | Significant improvement sustained at 6 months in both groups; no significant between-group difference | Mild transient hyperpigmentation in a small minority |
A 2025 systematic review pooled 17 studies covering 448 patients treated with the 1927 nm wavelength, finding consistent improvement in pigmentation, texture, and scar appearance with an acceptable safety profile — while judging most included studies at moderate to high risk of bias and calling for protocol standardization [7]. Two things should temper the numbers. First, nearly all studies report improvement in severity scores, not clearance. Second, longer-term recurrence rates are under-reported, so the honest conclusion for a clinic is: the evidence supports meaningful lightening with a manageable side-effect profile, provided patients are selected and counseled correctly.
Who Is a Good Candidate — and Who Isn’t?
Patient selection is where outcomes are actually decided. The most important variable is Fitzpatrick skin type. Patients with lighter skin types (I–III) generally tolerate the treatment well and respond predictably. Patients with darker skin types (IV–VI) can still be treated, but their melanocytes are more reactive, and the risk of PIH is meaningfully higher — these patients typically require more conservative energy settings, test spots, and sometimes a decision to avoid laser treatment altogether in favor of topicals. Encouragingly, careful low-energy settings have shown promise even here: a 2020 retrospective photographic review treated 61 patients with Fitzpatrick types IV–VI who already had PIH using a low-energy 1927 nm protocol, reporting a mean improvement of 43% with no observed side effects [8].
A history of PIH from previous procedures is a strong caution signal, as is active inflammation, recent sun exposure, or unrealistic expectations. The type of pigment also matters:
| Czynnik | Favorable for 1927 nm | Less favorable |
|---|---|---|
| Pigment depth | Epidermal (superficial) | Deep dermal component |
| Typ skóry | I–III | IV–VI (needs caution) |
| PIH history | Nic | Previous PIH |
| Trigger control | Sun protection routine in place | Ongoing high UV exposure |
| Oczekiwania | „Lightening and management” | „Permanent removal” |
Pigment depth is assessed clinically — a Wood’s lamp examination (epidermal pigment fluoresces more brightly) supported by dermoscopy is the standard office workup, and it directly feeds the prognosis conversation: epidermal melasma responds best to a superficial wavelength like 1927 nm, while a strong dermal component predicts partial response and faster relapse.
Hormonal stability is another practical consideration: patients with rapidly changing hormonal triggers (for example, planned pregnancy) should understand how this may affect timing and durability of results. A test spot in an inconspicuous area is a sensible precaution for any borderline candidate. The consultation should explicitly cover all five rows of this table. Patients who cannot commit to daily photoprotection, in particular, are poor candidates regardless of skin type, because uncontrolled UV exposure will undo results faster than any laser can produce them.
How Many Sessions Are Needed? Treatment Protocol and Downtime
A typical fractional 1927 nm session follows a predictable sequence, though exact parameters must always follow the device’s instructions for use and the operator’s clinical judgment:
- Step 1 — Assessment. Confirm the diagnosis (distinguish melasma from PIH, solar lentigines, and dermal pigmentation), classify pigment depth with Wood’s lamp and dermoscopy, and document baseline photography and, ideally, a MASI score.
- Step 2 — Preparation. Advise patients to pause photosensitizing topicals as appropriate, enforce strict pre-treatment sun avoidance, and apply topical anesthetic before the session.
- Step 3 — Treatment. Deliver low-energy, low-density fractional passes over the affected area. Conservative settings are standard first-line practice, particularly in darker skin types or at the first session. As a published reference point, the melasma pilot study used 10–20 mJ pulse energies at 4-week intervals [6] — study settings, not a universal prescription.
- Step 4 — Post-treatment care. Patients can expect redness, bronzing, and micro-crusting; social downtime is typically about one week. During this window, gentle cleansing, barrier-repair moisturizers, and absolute sun avoidance with broad-spectrum SPF are essential.
- Step 5 — Maintenance. Published protocols typically space sessions about one month apart, often as a series of three [7], with the final interval set per the device’s instructions for use and clinical response. Combination with topicals such as tranexamic acid or hydroquinone under medical supervision is standard maintenance practice — with the caveat from the RCT above that laser-assisted TXA delivery has not proven additive [3].
In terms of visible change, patients typically go through a bronzing phase in the first week as the treated micro-columns shed, followed by gradual lightening over the following two to four weeks — which is why clinics should schedule standardized follow-up photography at around four to six weeks after each session rather than judging results immediately. For patient counseling, it helps to break the typical week down into stages (timelines vary with energy, density, and skin type):
| Gdy | What most patients see | What it means |
|---|---|---|
| Day 0 | Redness, warmth, mild sensitivity | Normal immediate response to fractional treatment |
| Days 1–3 | Bronzing and a sandpaper-like texture as micro-columns form | Treated columns separating; no picking or exfoliating |
| Days 4–7 | Surface changes settle; skin looks clearer | End of typical social downtime of about one week |
| Tygodnie 2–4 | Progressive lightening of treated pigment | Pigment clearance and remodeling continuing |
Clinics should build the one-week downtime into scheduling and pricing conversations from the very first consultation, so patients are never surprised by it.
Thulium vs. Laser Toning vs. Picosecond vs. IPL for Melasma
Clinics evaluating technologies for melasma should compare on the dimensions that actually matter — mechanism, evidence, PIH risk, and downtime — rather than marketing claims:
| Czynnik | 1927 nm thulium laser | Low-fluence QS Nd:YAG („laser toning”) | Picosecond laser | Ipl |
|---|---|---|---|---|
| Główny cel | Water (shallow resurfacing) | Melanin, subcellular photothermolysis | Melanin + photomechanical effect | Melanin + vascular |
| Typical role in melasma | Resurfacing + pigment lightening | The incumbent in Asian markets; gradual lightening over many sessions | Pigment + overall rejuvenation | Epidermal pigment, vascular component |
| PIH risk | Lower (water, not melanin, absorption) | Low per session — but chronic over-treatment is linked to mottled hypopigmentation [11] | Moderate (melanin-targeting) | Higher in darker skin types |
| Czas przestoju | ~1 week (bronzing, micro-crusting) | Żadne lub minimalne | ~few days to 1 week | Minimal for non-ablative settings |
| Sesje | ~3 per course | 10+ per course | 3–6 | 3–6 |
| Evidence for melasma | Growing clinical literature | Large Asian clinical base, mixed durability | Growing, often as combination therapy | Mixed; less consistent |
No device wins across every patient. The honest professional position is that device selection should follow the patient’s pigment depth, skin type, and tolerance for downtime — and that in many protocols, combination approaches outperform any single modality. For procurement, the practical question is not „which device is best overall” but „which device matches my patient base”: a clinic serving predominantly lighter skin types with high demand for resurfacing-adjacent treatments will weight the 1927 nm platform differently than a clinic whose patient base skews darker. Clinics weighing thulium against deeper ablative options can also read our thulium laser vs CO2 laser comparison, which covers recovery, results, and which platform to buy first in detail; the same platform family also treats acne scarring, covered in our thulium laser for acne scars evidence review.
Managing Recurrence and Patient Expectations
Melasma is chronic, and recurrence after successful laser treatment is well documented in the literature and in everyday practice. The longest published follow-up makes this concrete: in a retrospective analysis of 20 melasma patients treated with the 1927 nm fractional thulium fiber laser, mean MASI improved from 13.2 to 8.5, and twelve of twenty patients reported more than half their melasma cleared — yet among the fifteen patients successfully followed up, seven had recurred at a mean of about ten months, and two developed PIH [9]. Flaring is documented too: a 2026 case report describes melasma worsening and previously invisible pigment being „unmasked” after 1927 nm treatment, a reminder that even the gentler wavelength can provoke reactive pigment in susceptible patients [10]. A clinic that communicates this clearly will retain more satisfied patients than one that promises clearance. The practical message for patients is: „We can significantly lighten your melasma and keep it under control, but this condition tends to return, especially with sun or hormonal triggers, so maintenance is part of the treatment.”
Effective maintenance has three pillars. The first is photoprotection — daily broad-spectrum sunscreen, hats, and avoiding peak UV hours — which is non-negotiable for every melasma patient. The second is maintenance therapy: topical agents such as tranexamic acid or hydroquinone used under medical supervision between sessions, and for appropriate patients, oral tranexamic acid prescribed by a physician after screening for contraindications (personal or family history of thromboembolic disease is the key one). The third is realistic scheduling: some patients benefit from periodic maintenance sessions, while others do well on topicals alone after an initial laser course.
From a business perspective, honest expectation-setting is also the best retention strategy. Melasma is one of the few indications where the clinical truth and the business model point the same way: a short initial course (typically three monthly sessions) converts naturally into a maintenance relationship — periodic touch-up sessions plus home-care retail — for a condition that by definition needs managing for years. Patients primed for „management” stay engaged through maintenance visits; patients promised „cure” become sources of refund demands and negative reviews the first time a patch reappears. Documenting improvement objectively (standardized photos, MASI scoring) helps both the clinic and the patient see real progress over time, and it protects the clinic when results plateau.
What Clinics Should Look for in a 1927 nm Platform
For clinics ready to add melasma treatment to their service menu, the device decision should be made on verifiable factors rather than brochure claims:
- Documented specifications — confirmed 1927 nm output, adjustable energy and density settings, and fractional scan patterns sized for facial work.
- Szkolenie — structured clinical training for operators, including energy selection by skin type and PIH risk management.
- Service and support — accessible technical service, reasonable response times, spare-parts availability in your region, and clarity on warranty terms and expected tube or consumable lifetimes.
- Regulatory documentation — verify the device’s regulatory status for your specific market before purchase, and treat marketing materials as a starting point for due diligence, not as evidence of clearance.
- Clinical and marketing support — patient education materials and realistic outcome photography help set expectations from day one. A platform vendor that trains your team on energy selection for different skin types — not just device operation — reduces early-treatment complications and shortens the learning curve considerably.
Mico Aes builds its 1927 nm platforms factory-direct — browse the 1927 nm thulium laser category for current configurations and specification checkpoints to benchmark any vendor against.
If you are evaluating a 1927 nm platform for melasma treatment at your clinic, browse our 1927 nm thulium laser system (also available as a dual 1927 + 1550 nm fractional platform), and share your patient profile, skin type distribution, and current service menu with our team — we can help you assess whether this technology fits your practice and what a realistic treatment protocol would look like.
Często zadawane pytania
How many sessions of thulium laser are needed for melasma?
Published cohorts often show visible improvement after one to two sessions, but the number of sessions depends on pigment depth, skin type, and how well the patient maintains sun protection. Most protocols are planned as a short initial course — commonly three monthly sessions — with maintenance as needed.
How long does it take to see results from a 1927 nm laser for melasma?
Lightening typically becomes visible as the micro-crusting resolves over the one-week healing period, with further improvement over the following weeks. Objective scoring (such as MASI) in studies captures improvement after each session.
Can thulium laser make melasma worse?
Yes, it can — the risk is reduced, not zero. Any laser can trigger PIH in susceptible patients, which is why skin typing, conservative settings, and test spots matter. A published case report documents melasma flaring and „unmasking” of previously invisible pigment after 1927 nm treatment [10]. The 1927 nm wavelength is chosen specifically because its water absorption lowers this risk relative to melanin-targeting wavelengths — but honest counseling includes the possibility of a flare.
Can thulium laser be combined with other melasma treatments?
Yes — combination maintenance is common clinical practice, but precision matters here: in the split-face RCT cited above, laser-assisted TXA delivery added no significant benefit over the laser alone [3]. Topical maintenance with agents such as tranexamic acid or hydroquinone under medical supervision remains standard adjunctive care, and oral tranexamic acid may be prescribed by a physician for suitable patients — but clinics should present these as parts of long-term melasma management rather than proven boosters for this specific laser.
Is thulium laser safe for darker skin types?
It can be used with caution in Fitzpatrick types IV–VI, but energy settings must be more conservative and PIH risk carefully weighed. A 2020 study of 61 Fitzpatrick IV–VI patients with existing PIH reported a mean 43% improvement with low-energy 1927 nm treatment and no observed side effects [8]. Some darker-skinned patients are better served by topical-first protocols, and a qualified assessment should decide.
Will melasma come back after laser treatment?
Recurrence is common because melasma is a chronic condition driven by UV, hormones, and genetics. In the longest published follow-up, nearly half of followed patients recurred at a mean of about ten months [9]. Maintenance — photoprotection, topical therapy, and periodic sessions where appropriate — is part of the treatment, not an optional extra.
Referencje
Jang YH, Park JY, Park YJ, Kang HY. Changes in melanin and melanocytes in mottled hypopigmentation after low-fluence 1,064-nm Q-switched Nd:YAG laser treatment for melasma. Ann Dermatol. 2015;27(3):341-343. doi:10.5021/ad.2015.27.3.341
Kurmuş GI, Tatlıparmak A, Aksoy B, Koç E, Aşiran Serdar Z, Ergin C. Efficacy and safety of 1927 nm fractional thulium fiber laser for the treatment of melasma: a retrospective study of 100 patients. J Cosmet Laser Ther. 2019;21(7-8):408-411. doi:10.1080/14764172.2019.1683581
Lee HM, Haw S, Kim JK, Chang SE, Lee MW. Split-face study using a 1,927-nm thulium fiber fractional laser to treat photoaging and melasma in Asian skin. Dermatol Surg. 2013;39(6):879-888. doi:10.1111/dsu.12176
Wanitphakdeedecha R, Sy-Alvarado F, Patthamalai P, Techapichetvanich T, Eimpunth S, Manuskiatti W. The efficacy in treatment of facial melasma with thulium 1927-nm fractional laser-assisted topical tranexamic acid delivery: a split-face, double-blind, randomized controlled pilot study. Lasers Med Sci. 2020;35(9):2015-2021. doi:10.1007/s10103-020-03045-8
Wind BS, Kroon MW, Meesters AA, et al. Non-ablative 1,550 nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled split-face study. Lasers Surg Med. 2010;42(7):607-612. doi:10.1002/lsm.20937
Kroon MW, Wind BS, Beek JF, et al. Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled pilot study. J Am Acad Dermatol. 2011;64(3):516-523. doi:10.1016/j.jaad.2010.01.048
Polder KD, Bruce S. Treatment of melasma using a novel 1,927-nm fractional thulium fiber laser: a pilot study. Dermatol Surg. 2012;38(2):199-206. doi:10.1111/j.1524-4725.2011.02178.x
Thulium laser (1927 nm) for dermatological conditions: a systematic review. Lasers Med Sci. 2025. doi:10.1007/s10103-025-04781-5
Bae YC, Rettig S, Weiss E, Bernstein L, Geronemus R. Treatment of post-inflammatory hyperpigmentation in patients with darker skin types using a low energy 1,927 nm non-ablative fractional laser: a retrospective photographic review analysis. Lasers Surg Med. 2020;52(1):7-12. doi:10.1002/lsm.23173
Niwa Massaki AB, Eimpunth S, Fabi SG, Guiha I, Groff W, Fitzpatrick R. Treatment of melasma with the 1,927-nm fractional thulium fiber laser: a retrospective analysis of 20 cases with long-term follow-up. Lasers Surg Med. 2013;45(2):95-101. doi:10.1002/lsm.22100
Melasma flaring and unmasking after treatment with a 1,927-nm non-ablative fractional thulium fiber laser. Cureus. 2026. doi:10.7759/cureus.110920
